|
|
|
|
|
Consumer Guides |
Government Guides |
Consumer News |
Consumer Guide
Index
Submit Article
Consumer News Articles on
Products and Services
Auctions
Adoption
Auto
Biology
Business
Business
Transportation
Directory
Presidential
Address:
Women's Small Business
Owners
Cell Phones
Computer
Consumer News Articles
Cosmetic Surgery and Financing
Culture
Digital Photography
Disabilities
National
Disability Employment
Awareness Month
Disaster Help
Guide
to help
Rebuild Your Home
DVD's
Earthquakes
Electronics
Employment
Administrative Service Managers
Engineering,
Science, Computer
Systems Managers
Education
Educational Software
Distributors
Original Educational
Software
Initiative by
President Bill Clinton
Energy
Presidential Energy Address
April 2005
Spectrally
Selective
Low-E Glass
Fashion
Financial
Currency:
Buying, Selling
Redeeming
E-Commerce
Associations
Directory
Fair and
Accurate Credit
Transaction Act of 2003
Merchant
Account Services
Costs and Fees
Fishing
Government Info
Homeland Security
Health
FDA
News Digest
Dec. 03
Contaminated food warnings;
New Drug Treatments ... more
Health
Insurance
HIPPA
Government Health Guides
Vioxx
Identity Theft
Consumer
Confidential:
The Privacy Story
New
Law Signed
By President Bush
Information
Insurance
Jets: Private
Jewelry
Legal Guides
Machinery
Farm,
Food Processing
Packaging
Medicare
The Medicare Prescription
Drug Improvement and
Modernization Act of 2003
Patents & Trademarks
Patents, Trademarks, Copyrights
Press Releases
For Immediate Release
Politics
Real Estate
American
Dream
Downpayment Act
Financing Energy
Efficient Homes
Sustainable Design:
Energy Efficient Homes
Soccer
Soccer.com
Free
Soccer Posters
Shopping
Specialty Directories
Taxes
Technology
Time
Toxicology
Asbestos Issues
Legislative
Analysis
-
Asbestos Information Act of 1988
H.R. 5442
Travel
Tips
For Women
Traveling Alone
Other Online Guides
e-Commerce
Shopping
________
Disclaimer
Vioxx (rofecoxib)
Source: FDA
Merck & Co., Inc. announced a voluntary withdrawal of Vioxx (rofecoxib) from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events (including heart attack and stroke) in patients on Vioxx. Vioxx is a prescription COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by FDA in May 1999 for the relief of the signs and symptoms of osteoarthritis, for the management of acute pain in adults, and for the treatment of menstrual symptoms. Vioxx was later approved for the relief of the signs and symptoms of rheumatoid arthritis in adults and children.
- Statement by Dr. Steven Galson, Acting Director, Center for Drug Evaluation and Research (CDER), Regarding November 18, 2004, Committee on Finance of the U.S. Senate Hearing on Drug Safety and the Worldwide Withdrawal by Merck & Co., Inc., of Vioxx. FDA Statement (11/18/2004)
- Congressional Statement on Vioxx and Drug Safety (Posted 11/18/2004)
- FDA releases a statement on Vioxx and recent allegations, and on the Agency’s continued commitment to sound science and peer review. FDA Statement (Posted 11/17/2004)
- Slide Presentation by Sandra Kweder, M.D., November 10, 2004. [HTML] [PowerPoint] (Posted 11/10/2004)
- FDA Acts to Strengthen the Safety Program for Marketed Drugs. FDA Statement (11/5/2004)
- 9/30/2004
Study Report
(Posted 11/2/2004)
- FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Withdraws the Product. FDA News (9/30/2004)
- FDA Public Health Advisory: Safety of Vioxx (9/30/2004)
- Vioxx (rofecoxib) Questions and Answers (9/30/2004)
Vote:
There's a lot at
stake...